HK1206995A1 - Methods for increasing cftr activity - Google Patents

Methods for increasing cftr activity Download PDF

Info

Publication number
HK1206995A1
HK1206995A1 HK15107706.3A HK15107706A HK1206995A1 HK 1206995 A1 HK1206995 A1 HK 1206995A1 HK 15107706 A HK15107706 A HK 15107706A HK 1206995 A1 HK1206995 A1 HK 1206995A1
Authority
HK
Hong Kong
Prior art keywords
increasing
mucociliary clearance
subject
compounds
present disclosure
Prior art date
Application number
HK15107706.3A
Other languages
English (en)
Chinese (zh)
Inventor
M. Rowe Steven
Dransfield Mark
Original Assignee
The Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Uab Research Foundation filed Critical The Uab Research Foundation
Publication of HK1206995A1 publication Critical patent/HK1206995A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK15107706.3A 2012-04-06 2013-03-15 Methods for increasing cftr activity HK1206995A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261621043P 2012-04-06 2012-04-06
US61/621,043 2012-04-06
PCT/US2013/032268 WO2013151758A2 (en) 2012-04-06 2013-03-15 Methods for increasing cftr activity

Publications (1)

Publication Number Publication Date
HK1206995A1 true HK1206995A1 (en) 2016-01-22

Family

ID=49301152

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107706.3A HK1206995A1 (en) 2012-04-06 2013-03-15 Methods for increasing cftr activity

Country Status (8)

Country Link
US (2) US20150065539A1 (enExample)
EP (1) EP2833885A4 (enExample)
JP (1) JP6525203B2 (enExample)
CN (1) CN104619321A (enExample)
AU (2) AU2013243857A1 (enExample)
CA (1) CA2869257A1 (enExample)
HK (1) HK1206995A1 (enExample)
WO (1) WO2013151758A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690023A5 (de) * 1996-02-02 2000-03-31 Medichemie Ag Mittel zur Behandlung krankhafter Zellveränderungen der Nasenschleimhaut.
US20040266883A1 (en) * 1999-10-27 2004-12-30 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US7541466B2 (en) * 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
RS56894B1 (sr) 2008-08-13 2018-04-30 Vertex Pharma Farmaceutska kompozicija n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida i njeno ordiniranje
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
RU2012114323A (ru) * 2009-09-12 2013-10-20 РЕКИТТ БЕНКИЗЕР ЭлЭлСи Применение гвайфенезина для ингибирования секреции муцина
KR101924162B1 (ko) * 2010-03-15 2018-11-30 버지니아 커먼웰스 유니버시티 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손
CN103180298A (zh) * 2010-03-19 2013-06-26 沃泰克斯药物股份有限公司 N-[2,4-双(1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧代喹啉-3-甲酰胺的固体形式
ME03652B (me) * 2011-05-18 2020-07-20 Vertex Pharmaceuticals Europe Ltd Deuterisani derivati ivakaftora

Also Published As

Publication number Publication date
JP6525203B2 (ja) 2019-06-05
WO2013151758A2 (en) 2013-10-10
AU2018200192B9 (en) 2019-07-25
AU2013243857A1 (en) 2014-10-16
CA2869257A1 (en) 2013-10-10
US20150065539A1 (en) 2015-03-05
JP2015521157A (ja) 2015-07-27
AU2018200192A1 (en) 2018-02-01
US20170266177A1 (en) 2017-09-21
AU2018200192B2 (en) 2019-06-06
EP2833885A4 (en) 2015-12-16
CN104619321A (zh) 2015-05-13
US10300052B2 (en) 2019-05-28
EP2833885A2 (en) 2015-02-11

Similar Documents

Publication Publication Date Title
WO2014100764A3 (en) Methods of inhibiting prmt5
EP3398679A4 (en) Cluster supported catalyst and production method therefor
EP3036506A4 (en) Realtime activity suggestion from social and event data
EP3035800A4 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP3038635A4 (en) Systems, compositions, and methods for transplantation and treating conditions
BR112014028751A2 (pt) partícula encapsulada, e, método para formar uma partícula encapsulada.
EP3093361A4 (en) Bearing component, steel for bearing component, and production method for same
BR112015011139A2 (pt) partícula encapsulada, e, método para formar uma partícula encapsulada.
BR112014031787A2 (pt) composição, métodos de substituição e para produção de refrigeração e equipamento de refrigeração.
EP2670178A4 (en) Sense aiding method and system for cognitive radio
EP2741032A3 (en) Refrigerator and method for operating the same
EP3069290B8 (fr) Procede et systeme de controle lors de l'acces ou la sortie d'une zone
EP3122459A4 (en) Methods and systems for forming catalytic assemblies, and related catalytic assemblies
WO2013130963A8 (en) Compositions and methods for treating type iii gaucher disease
EP2961866A4 (en) Methods for the production of libraries for directed evolution
EP3093360A4 (en) Hot-formed member and process for manufacturing same
DK3910337T3 (da) Fremgangsmåde til at katalysere en enzym-katalyseret reaktion
EP3068389A4 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
BR112015009275A2 (pt) aparelho para cozer produtos, e, método de cozimento de produtos.
EP3083555A4 (en) Processes for the diazotization of 2,5-dichloroanilines
EP3315280A4 (en) Method for manufacturing substrate-integrated gasket
EP3027672A4 (en) Improved process for the preparation of modified poly(alkylene terephthalate) employing an in-situ titanium-containing catalyst
MX2016004393A (es) Derivados de carboxamida como compuestos pesticidas.
EP3052662A4 (en) Compositions, systems and methods for gene expression noise drug screening and uses thereof
EP3186270A4 (en) Cyclic urea compounds as granzyme b inhibitors